Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Spondyloarthritis family · A closer look at PsA

PsA with a complex medical history: decisions across specialties

Cancer, serious infections, liver or kidney disease, bowel inflammation and uveitis can change a PsA treatment discussion. The useful question is what each condition changes for this person, now.

Olga Goodman, MD · Sources checked 27 September 2026

Chapter 16 of 21

The essentials

Bring the details of previous illness, not just its name. Agree which specialist supplies the missing information, who coordinates the decision and what will trigger reassessment. A complex history calls for a shared plan, not an automatic ban on effective treatment.

A history of cancer needs specifics

Record the cancer type, treatment, remission status and current follow-up. EULAR's 2024 points to consider support timely appropriate treatment of active inflammatory arthritis when cancer is in remission, with an individual assessment and oncology input. They do not impose one universal waiting period. Active cancer is a different situation requiring a joint decision. 7

Ask what is known for your cancer and proposed therapy, and what remains uncertain. Evidence is uneven across drugs and cancer types, with much information coming from rheumatoid arthritis. Reassurance about one group should not be extended to every medicine or every tumour.

Previous serious infection and current illness

Tell the team what infection occurred, when, which organism was identified, what treatment was needed and whether it resolved. Also mention tuberculosis exposure, hepatitis and recurrent infections. Before some therapies, screening and preventive treatment may be needed; a past positive test is not the same as an active infection. 8

Ask for a written plan for fever or another suspected infection: whom to contact, what information to give and how the next dose will be decided. Do not treat every infection or every drug with the same stop-and-restart rule. Severe breathlessness, confusion or rapid deterioration needs urgent care rather than a routine message.

Liver and kidney disease: use current information

Bring recent results and the diagnosis behind them. A mildly abnormal test, chronic viral hepatitis, fatty liver and advanced liver disease are not interchangeable. Likewise, the degree and stability of kidney impairment matter. These details can change drug selection and monitoring. 10

Include non-prescription pain medicines, alcohol and supplements in the review. Ask whether dehydration, a new prescription or an intercurrent illness changes the plan. The purpose of monitoring is to detect a problem early, not to wait until you feel unwell.

Bowel disease and uveitis can change the treatment target

Tell the rheumatologist about diagnosed inflammatory bowel disease (IBD), previous uveitis and their current activity. A drug effective for joints or skin may not treat the bowel or eyes. Selection should consider the affected organs together; the gastroenterologist or ophthalmologist may need to help choose the strategy. 10, 11

Report persistent diarrhoea, blood in stool or unexplained weight loss rather than assuming a medicine or diet explains everything. A painful red eye, light sensitivity or a sudden visual change needs urgent assessment; it should not wait for the next routine arthritis visit.

Other details that can change a choice

Heart failure, a previous clot, cardiovascular events, demyelinating disease and pregnancy plans also belong in the history. They do not all have the same implications for every drug. Ask which feature changes the recommendation and what alternative is being considered. 10, 12

If surgery or another procedure is planned, tell the procedural team about all medicines and ask for a coordinated plan. The timing of interruption and restart depends on the drug, procedure and recovery. Do not borrow another patient's timetable.

Turn complexity into a clear next step

A useful joint plan identifies a decision and the information needed to make it. Keep a copy so that each appointment builds on the last rather than restarting the discussion.

Turn complexity into a clear next step
QuestionInformation to bring or agree
What is active now?PsA findings and current status of cancer, infection, bowel, eye or organ disease.
What changes the options?Previous treatments and harms; recent tests; specialist advice; the exact medicine being considered.
Who acts next?Coordinator; missing information and responsible team; interim treatment; review date and contact for deterioration.

Surgery, travel, infection: before, during, after — Free after registration →

Go deeper

Why a reassuring study is not a personal guarantee

People with serious comorbidities are often underrepresented in trials. Observational studies help, but treatment groups may differ before therapy starts: clinicians may choose a particular drug for people already judged to have lower risk. 7, 10

Ask whether evidence concerns the same disease, previous illness and medicine as yours. Good decisions acknowledge both the risk of treatment and the consequences of leaving active inflammation uncontrolled. If the decision is to wait for further information, ask what will be done in the meantime and when the decision will be revisited.

Questions for your visit

  1. Which part of my history actually changes this treatment choice?
  2. Do you need advice or records from oncology, infectious diseases, gastroenterology or ophthalmology?
  3. What screening, prevention and monitoring apply to this medicine?
  4. Who coordinates the decision, what is the interim plan and when will we review it?

When to seek urgent help

A painful red eye, light sensitivity or a sudden change in vision needs urgent assessment. A newly hot, swollen joint, especially with fever or feeling unwell, also needs prompt assessment.

Sources & evidence notes

Sources checked 27 September 2026

The dates identify the versions used. General guidance needs an individual decision; drug labels, age-specific indications and local vaccination schedules also matter.

  1. Sebbag E et al. EULAR points to consider: targeted therapies and a history of cancer. 2024.
  2. Fragoulis GE et al. EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections. 2022 recommendations. Ann Rheum Dis. 2023.
  3. Coates LC et al. GRAPPA treatment recommendations 2021. Nat Rev Rheumatol. 2022.
  4. Gossec L et al. EULAR PsA pharmacological treatment recommendations: 2023 update. Ann Rheum Dis. 2024.
  5. FDA. Warnings for JAK inhibitors: serious cardiovascular events, cancer, thrombosis and death. September 2021.

Educational information for patients and caregivers. This personal publication is not the clinic portal and does not provide individual diagnosis or treatment. Discuss medication changes with your own care team.

© 2026 Olga Goodman, MD · A RheumaView publication. Copying without attribution prohibited.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Care coordinationPsoriasisPsoriatic arthritisQuality of lifeSpondyloarthritis